Literature DB >> 319724

Efficacy of intermittent colchicine therapy in familial Mediterranean fever.

D G Wright, S M Wolff, A S Fauci, D W Alling.   

Abstract

Nine patients with familial Mediterranean fever (FMF) were admitted to a controlled, double-blind trial to determine if there are patients with this disease who are able to abort their acute episodes of pain and fever with short courses of colchicine taken at the onset of attacks. Five patients completed their treatment assignments, and colchicine was significantly effective in aborting the attacks of three but was ineffective in two. The remaining four patients could not be assessed because of insufficient numbers of courses. During the 10 months of the trial, 28 courses of colchicine and 31 of placebo were taken during the early stages of FMF attacks. Twenty-one (75%) colchicine courses were followed by attacks considered to have been aborted, compared to only three (10%) placebo courses. This trial shows that patients can recognize the prodrome of their FMF attacks and that some patients can consistently abort their attacks with short courses of colchicine taken at the very onset of symptoms.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 319724     DOI: 10.7326/0003-4819-86-2-162

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

Review 1.  Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review.

Authors:  Erkan Demirkaya; Burak Erer; Seza Ozen; Eldad Ben-Chetrit
Journal:  Rheumatol Int       Date:  2015-12-19       Impact factor: 2.631

2.  Efficacy of colchicine in familial Mediterranean fever is well established.

Authors:  J P Drenth
Journal:  BMJ       Date:  1996-07-27

3.  Familial Mediterranean fever--a progress report.

Authors:  S E Goldfinger
Journal:  West J Med       Date:  1977-07

Review 4.  Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis.

Authors:  Cailin Henderson; Raphaela Goldbach-Mansky
Journal:  Curr Opin Rheumatol       Date:  2010-09       Impact factor: 5.006

5.  Colchicine therapy for nephrotic syndrome due to familial Mediterranean fever.

Authors:  G Skrinskas; R A Bear; A Magil; K Y Lee
Journal:  Can Med Assoc J       Date:  1977-12-17       Impact factor: 8.262

Review 6.  Interventions for reducing inflammation in familial Mediterranean fever.

Authors:  Xi Yin; Fangyuan Tian; Bin Wu; Ting Xu
Journal:  Cochrane Database Syst Rev       Date:  2022-03-29

7.  Colchicine use for familial Mediterranean fever. Observations associated with long-term treatment.

Authors:  R S Peters; T J Lehman; A D Schwabe
Journal:  West J Med       Date:  1983-01

8.  Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever--a randomized controlled noninferiority trial.

Authors:  Adem Polat; Cengizhan Acikel; Betul Sozeri; Ismail Dursun; Ozgur Kasapcopur; Nesrin Gulez; Dogan Simsek; Mehmet Saldir; Ipek Dokurel; Hakan Poyrazoglu; Sevcan Bakkaloglu; Ali Delibas; Zelal Ekinci; Nuray A Ayaz; Yasar Kandur; Harun Peru; Yasemin G Kurt; Safiye R Polat; Erbil Unsal; Balahan Makay; Faysal Gok; Seza Ozen; Erkan Demirkaya
Journal:  Arthritis Res Ther       Date:  2016-04-07       Impact factor: 5.156

9.  Subclinical inflammation in a case of menstruation-induced familial Mediterranean fever: A case report.

Authors:  Kazusato Hara; Yushiro Endo; Midori Ishida; Yuya Fujita; Sosuke Tsuji; Ayuko Takatani; Toshimasa Shimizu; Remi Sumiyoshi; Takashi Igawa; Masataka Umeda; Shoichi Fukui; Ayako Nishino; Shin-Ya Kawashiri; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Kiyoshi Migita; Atsushi Kawakami; Tomohiro Koga
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

10.  Interventions for reducing inflammation in familial Mediterranean fever.

Authors:  Bin Wu; Ting Xu; Youping Li; Xi Yin
Journal:  Cochrane Database Syst Rev       Date:  2018-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.